Salute e Benessere

Avaz Joins the PRC-Saltillo Community, Expanding Global AAC Access and…

Narayanan Ramakrishnan, CEO of Avaz, added, "Together, we're uniquely positioned to expand access to AAC and share knowledge across borders. For both our customers and our internal teams, this means new opportunities to learn, innovate, and grow together." Narayanan Ramakrishnan, CEO of Avaz, added, "Together, we're uniquely positioned to expand access to AAC and share knowledge across borders. For both our customers and our internal teams, this means new opportunities to learn…
PR Newswire
23/10/2025

Orion and Abzena announce exclusive commercial license for Abzena’s antibody

ORION CORPORATION PRESS RELEASE23 OCTOBER 2025 at 15:30 EEST Orion and Abzena announce exclusive commercial license for Abzena’s antibodyOrion Corporation (“Orion”) and Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive, focused commercial license to one of Abzena’s monoclonal antibodies (mAbs) that targets a cancer of high clinical unmet need. The antibody will strengthen Orion’s broad...
Nasdaq GlobeNewswire
23/10/2025

Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer…

Click here to view the custom infographic of the Izotropic Corporation editorial. Clickhereto view the custom infographic of the Izotropic Corporationeditorial. The fusion of artificial intelligence (AI) and three-dimensional (3D) medical imaging is redefining diagnostic accuracy and efficiency. While traditional mammography has saved countless lives, its two-dimensional imaging format and need for physical compression limit visibility of internal structures, particularly in complex...
PR Newswire
23/10/2025

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for…

"This designation underscores the potential of our approach in Myelodysplastic Syndromes and supports our commitment to developing new treatment options for patients living with MDS," said David Bearss, PhD, Chief Executive Officer of Halia Therapeutics. "Ofirnoflast represents a first-in-class approach to modulating inflammasome biology, an upstream driver of inflammation, with the goal of restoring healthy bone marrow function." "This designation underscores the…
PR Newswire
23/10/2025

Emboline, Inc. Completes Enrollment in U.S. Pivotal IDE Trial of the Emboliner®…

"We are very excited to have completed enrollment in this important trial, which we hope will bring us closer to being able to offer our patients comprehensive embolic protection for TAVR and other structural heart procedures," said Tamim Nazif, MD, Director of Clinical Research in Cardiology at Columbia University Irving Medical Center and Co-Principal Investigator for the Protect the Head to Head study. "The use of a full body embolic filter with debris capture and removal will…
PR Newswire
23/10/2025

Dr. Scott Leune to Bring His Practice Mastery Seminars to the UK

"For years, UK dentists have traveled to my seminars or joined my coaching programs remotely, and I knew it was time to bring these events to them," said Dr. Leune. "The UK dental market is underserved when it comes to the business of dentistry. Most dentists receive exceptional clinical training but very little guidance on how to build, grow, and sustain a profitable practice. My goal is to close that gap and provide UK dentists with the same strategies that have already…
PR Newswire
23/10/2025

TetraScience Launches Scientific AI Lighthouse Program with Takeda as Founding…

As a founding SAIL partner, Takeda will have first-mover access to TetraScience's full range of data and AI capabilities to accelerate AI-powered drug discovery, reduce CMC cycle times, enable in silico modeling, and increase scientist productivity through the use of agentic AI. The program is designed to enable biopharma organizations to bring more products to market at lower cost and risk by increasing productivity and improving candidate quality. As a founding SAIL partner, Takeda will…
PR Newswire
23/10/2025

Orion and Abzena Announce Exclusive Commercial License for Abzena's Antibody

Campbell Bunce, Chief Scientific Officer of Abzena, said, "We are delighted to have partnered with Orion on the design and development of our CHAb-designed mAb to support their extensive oncology-focused Research and Development pipeline. Using our uniquely integrated developability approach along with our streamlined AbZelectPRO™ CLD platform, we were able to design a de-risked lead antibody that offers Orion's program the best chances of success in the clinic." Campbell Bunce…
PR Newswire
23/10/2025

World's leading nutrition researchers discuss future lines of research on nuts…

The experts presented the latest research on nuts and dried fruit in relation to the main health challenges faced by the population, as well as new possible underlying mechanisms. The experts presented the latest research on nuts and dried fruit in relation to the main health challenges faced by the population, as well as new possible underlying mechanisms. During the event, an update of the NUTPOOL study, funded by the INC, was presented. This global initiative combines data from around one...
PR Newswire
23/10/2025

Amphista Therapeutics announces three key strategic leadership appointments to…

Appointments for SVP of Clinical Operations, VP of Translational Science, and Head of Project and Portfolio Management will strengthen Amphista’s clinical development capabilities and accelerate its ambition to bring its innovative Targeted Glue™ protein degraders to patients Cambridge, UK, 23 October 2025– Amphista Therapeutics, a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the appointments of three senior leaders who...
Nasdaq GlobeNewswire
23/10/2025

TRIDENT, a dedicated stroke outcomes trial in patients with a history of…

GMRx2 significantly reduced the risk of recurrent stroke when added to standard of care compared to placeboTrial results were presented during a plenary session of the World Stroke Congress 2025 in Barcelona London, UK, Boston, MA, 23 October 2025– George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today announced that positive results from the investigator-initiated TRIDENT trial have been shared...
Nasdaq GlobeNewswire
23/10/2025

Alife Health Receives CE Mark Under European Medical Device Regulation for…

Embryo Predict was developed to address one of the most important, yet highly subjective, aspects of IVF: embryo grading. Traditional embryo assessment relies on manual observation of morphology, which can vary significantly between embryologists. Embryo Predict digitizes and standardizes this process, adding an additional layer of quality control and harnessing the power of AI to detect patterns of success from a vast dataset, providing data-driven insights that go beyond the limits of the…
PR Newswire
23/10/2025

ANTARES VISION GROUP TO SHOWCASE FULL-STACK TRACEABILITY SOLUTIONS AT THE 40th…

As a trusted partner in digitalization,Antares Vision Groupwill present its vision and solutions forend-to-end traceability, spanningserialization, aggregation, supply chain compliance, and hospital-level medication management. The company's approach demonstrates how GS1 standards allow each product to maintain aunique digital identitythroughout its lifecycle, enablingtransparency, regulatory compliance, and actionable dataat every step. "The true value of...
PR Newswire
23/10/2025

PCI Biotech update

Reference is made to the company’s announcements dated 18 thAugust 2025 and 25 thSeptember 2025, as well as the interim report for the first half of 2025 published on 29 thAugust 2025. As previously communicated, current activities are focused on the evaluation of a new bioprocessing technology by an undisclosed party, conducted under a material transfer agreement without financial terms. The company’s limited operations and the group’s future rely on continued interest under the...
Nasdaq GlobeNewswire
23/10/2025

RIMAN Officially Launches in London, Setting the Stage for European Market…

Formulated with heritage Korean ingredients such as RIMAN's patented plant, Giant BYoungPool™, and Jeju Lava Energy Water, RIMAN's products combine nature and science through advanced formulation technologies and a sustainability-focused vision. Formulated with heritage Korean ingredients such as RIMAN's patented plant, Giant BYoungPool™, and Jeju Lava Energy Water, RIMAN's products combine nature and science through advanced formulation technologies and a sustainability-focused vision...
PR Newswire
23/10/2025

Vantage Hemp Co. Strengthens Global Footprint with Initiation of European…

U.S. producer and WELDING GmbH & Co. KG partner to expand cannabinoid access in Europe Vantage Hemp Co. (“Vantage” or “the Company”), a globally accredited cannabinoid manufacturer, has initiated the submission process for its Certificate of Suitability (CEP) to the European Directorate for the Quality of Medicines (EDQM) and its Active Substance Master File (ASMF) to the European Medicines Agency (EMA). These applications place Vantage among the first global...
Nasdaq GlobeNewswire
23/10/2025

RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER

NEWS RELEASE Milan, 23 October 2025– Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, 2026 and will be based in the Group’s headquarters in Milan.Mike McClellan, an American national, is a seasoned CFO in the pharmaceutical industry with nearly 30 years of experience across various geographies. Most recently, he served as CFO of Almirall (2019-2025) where he played a pivotal role in...
Nasdaq GlobeNewswire
23/10/2025

Pharming Group to report third quarter 2025 financial results and provide…

Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET. To participate in the conference call or to watch the live webcast, please register in...
Nasdaq GlobeNewswire
23/10/2025

THERANEXUS : THX Pharma announces the launch of a capital increase with…

Subscription and guarantee commitments totaling €5.9 million, representing 75.5% of the envisaged capital increase Subscription price: €1.80 per share, representing a 29.4% discount to the closing price of the share on October 22, 2025 Subscription ratio: 6 new shares for 13 existing shares Detachment of preferential subscription rights on October…
Actusnews Wire
23/10/2025

Essity: Interim Report Quarter 3, 2025

CEO'S COMMENTS CEO'S COMMENTS Our efforts to drive growth and reduce costs have yielded results and the third quarter developed favourably in continued challenging market conditions. In parallel, we are today launching measures aimed at creating better conditions for profitable growth - an organizational change and a cost savings program. Positive organic sales growth Organic growth was positive compared with the third quarter of the previous year, mainly driven by higher prices...
PR Newswire
23/10/2025

Changes to the Roche Enlarged Corporate Executive Committee

Nina Schwab-Hautzinger rejoins Roche from her role at BASF as Head of Corporate Communications and Government Relations. During her previous thirteen year tenure at Roche, Nina Schwab-Hautzinger held various communications leadership roles such as Head of Corporate Brand & Communications at the Group level and Head of Communications & Public Affairs for Pharma in Germany. She has also led the healthcare practice in a strategic communications consultancy in Singapore.Nina...
Nasdaq GlobeNewswire
23/10/2025

Nicox Provides First Half 2025 Financial Results

Press ReleaseNicox Provides First Half 2025 Financial Results New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and ChinaCompany believes that it can finance its existing operations for at least 12 months and expects to fully repay existing financial debts in 2026October 23, 2025 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today...
Nasdaq GlobeNewswire
23/10/2025

Essity strengthens conditions for profitable growth

The organizational change will simplify Essity's structure and create end-to-end accountability. This will further enhance customer and consumer focus, increase speed, agility, and operational efficiency. The change facilitates increased strategic focus on the product categories and segments with the greatest potential for profitable growth. The organizational change will simplify Essity's structure and create end-to-end accountability. This will further enhance customer and consumer focus,...
PR Newswire
23/10/2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth…

Basel, 23 October 2025 Group salesgrew by 7% 1at constant exchange rates (CER; 2% in CHF) in the first nine months, driven by high demand for our innovative medicines and diagnostics. Pharmaceuticals Divisionsales rose by 9% (4% in CHF) due to continued high growth in sales of medicines for the treatment of severe diseases; Phesgo (breast cancer), Xolair (food allergies), Hemlibra (haemophilia A), Vabysmo (serious eye diseases) and Ocrevus (multiple sclerosis) were the top...
Nasdaq GlobeNewswire
23/10/2025
Altri  Comunicati